To include your compound in the COVID-19 Resource Center, submit it here.

Boston Biomedical, Dainippon Sumitomo deal

Dainippon received an option to license exclusive rights to develop and commercialize

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE